Anti-Claudin 18.2 antibody YH005

YH005 is an anti-Claudin 18.2 antibody generated using our Claudin 18.2 knock-out mice. We have out-licensed YH005 to RemeGen for the development of RC118. RC118 is a potentially first-in-class ADC (antibody-drug conjugate) for the treatment of solid tumors. It has obtained TGA approval for clinical trials in Australia and is currently under the IND application process in China.

Back to top